Testosterone therapy can meaningfully improve sexual desire in postmenopausal women, yet most doctors never bring it up — because there is not a single FDA-approved testosterone product designed for women in the United States. That is not a typo. More than 30 FDA-approved testosterone formulations exist for men, and zero for women. The result is a strange clinical limbo: the evidence for treating low libido after menopause is solid enough that international guidelines endorse it, but American physicians face real liability concerns prescribing male-formulated products off-label at adjusted doses.
Many simply choose not to offer it at all. Consider a 58-year-old woman who has been on estrogen-based hormone replacement therapy for hot flashes and sleep disruption, and it has helped — but her sexual desire, once a normal part of her life, has not returned. Her doctor may never mention testosterone as an option, not because the treatment does not work, but because the regulatory and medicolegal landscape makes prescribing it uncomfortable. This article examines why that gap exists, what the evidence actually supports, the safety concerns that remain unresolved, a promising drug in development that may change the equation, and what women should know before seeking testosterone therapy on their own.
Table of Contents
- Why Don’t Doctors Offer Testosterone Therapy for Women?
- What Does Testosterone Actually Treat in Women — and What Doesn’t It Treat?
- The Safety Profile — What We Know and What We Don’t
- How Women Are Getting Testosterone Now — and the Tradeoffs
- What Expert Guidelines Actually Recommend
- A New Drug That Could Change the Landscape
- What This Means for Brain Health and the Road Ahead
- Conclusion
- Frequently Asked Questions
Why Don’t Doctors Offer Testosterone Therapy for Women?
The short answer is risk — not primarily medical risk, but professional and regulatory risk. When a physician prescribes a drug off-label, they assume greater liability if something goes wrong. Without FDA-approved female formulations, there are no standardized dosing guidelines for women. A doctor prescribing testosterone cream originally manufactured for men must estimate the correct dose, often dividing it to roughly one-tenth of the male dose, and monitor carefully. Some physicians have described this situation bluntly, saying the FDA is failing women by not creating a dedicated regulatory pathway for female testosterone therapy.
There is also a knowledge gap. Many primary care physicians and even some gynecologists received little training on androgen deficiency in women. Testosterone is still reflexively categorized as a “male hormone” in much of clinical education, despite the fact that women’s ovaries and adrenal glands produce it naturally and that levels decline significantly with age and after surgical menopause. The combination of no approved product, no standardized protocol, limited training, and unresolved long-term safety questions creates a situation where the path of least resistance for most doctors is simply not to raise the topic. The women who do receive testosterone therapy often find it through menopause specialists, endocrinologists, or — increasingly — wellness clinics and compounding pharmacies that operate outside the conventional medical system.
What Does Testosterone Actually Treat in Women — and What Doesn’t It Treat?
The only evidence-backed indication for testosterone therapy in cisgender women is hypoactive sexual desire disorder, or HSDD — a persistent, distressing loss of sexual desire that is not explained by relationship problems, medication side effects, or other medical conditions. This is not a vague wellness complaint. HSDD is a recognized clinical diagnosis, and the data supporting testosterone’s benefit here is robust enough that guidelines from the International Menopause Society, NICE in the United Kingdom, and the International Society for the Study of Women’s Sexual Health all endorse its use in postmenopausal women when estrogen therapy alone has not restored sexual desire. Women typically notice improvement in sexual function six to eight weeks after starting treatment, with maximal effects at about 12 weeks. However, testosterone’s reputation has expanded well beyond libido in popular health media and at wellness clinics.
Claims that it improves mood, sharpens cognition, builds muscle tone, increases energy, or accelerates metabolism in women are not yet backed by rigorous clinical data. This distinction matters enormously, especially for readers of a brain health site. While some preliminary research has explored whether androgens play a role in cognitive function and neuroprotection, there is currently no clinical evidence sufficient to recommend testosterone therapy for cognitive decline or dementia prevention in women. If a clinic is marketing testosterone as a brain-boosting or anti-aging treatment for women, that claim is running ahead of the science. The honest answer is that we do not yet know whether testosterone has meaningful cognitive benefits in women, and assuming it does could lead to unnecessary risk.
The Safety Profile — What We Know and What We Don’t
Short-term transdermal testosterone use — meaning patches or creams applied to the skin — appears relatively safe based on the clinical trials that exist. Studies have not shown adverse effects on blood pressure, lipid profiles, liver function, renal function, or blood cell counts at appropriate female doses. The most common side effects are increased acne and unwanted hair growth, which are generally mild and reversible when the dose is adjusted. The problems emerge at higher doses and over longer time horizons. At supraphysiologic levels — doses that push testosterone above the normal female range — women may experience voice deepening and clitoral enlargement, some of which can be irreversible. This is one reason that expert guidelines from 12 major medical societies recommend against hormone pellets, which are inserted under the skin and release testosterone at rates that cannot be adjusted or reversed once implanted.
Pellets are unregulated, carry a higher risk of pushing levels too high, and have become popular at wellness clinics despite these concerns. The most significant unknown is long-term safety. Cardiovascular risk and breast cancer risk from sustained testosterone use in women have not been established in either direction. There are no large, long-duration randomized trials that definitively answer whether years of testosterone therapy increases or decreases these risks. This uncertainty is the primary reason the FDA has not approved a women’s formulation. Monitoring recommendations from expert guidelines call for measuring testosterone levels at baseline, again at three to six weeks after starting therapy, and every six months thereafter — partly to screen for overuse and partly because the absence of long-term data makes ongoing surveillance essential.
How Women Are Getting Testosterone Now — and the Tradeoffs
In the absence of an FDA-approved option, women seeking testosterone therapy generally end up in one of three channels, each with distinct tradeoffs. The first is a prescription from a knowledgeable physician — typically a menopause specialist or endocrinologist — who prescribes a male-formulated product off-label at a reduced dose. This is the most medically conservative route. The physician monitors blood levels, adjusts dosing, and watches for side effects. The limitation is access: many women do not have a menopause specialist nearby, and their primary care doctor may be unwilling to prescribe off-label. The second channel is compounding pharmacies, which create custom testosterone formulations — often creams or troches — tailored to a specific dose.
Compounded hormones are not FDA-regulated in the same way as commercial pharmaceuticals, meaning there is less oversight of potency, purity, and consistency. Quality varies between pharmacies. Some are excellent; others have been found to produce formulations with wildly inconsistent hormone concentrations. The third channel is wellness clinics and anti-aging practices, which may offer testosterone as part of a broader hormone optimization package. These clinics sometimes use pellet implants, which, as noted, carry the highest risk of supraphysiologic dosing and are recommended against by major guidelines. The appeal of these clinics is that they say yes when conventional doctors say no — but that accessibility comes with less rigorous safety oversight and, in some cases, marketing claims that outpace the evidence.
What Expert Guidelines Actually Recommend
The most authoritative guidance comes from a Global Position Statement produced by an international task force convened by the International Menopause Society. This document, endorsed by 12 major medical societies worldwide, lays out a conservative but clear framework. Testosterone therapy can be considered for postmenopausal women with HSDD when hormone replacement therapy alone has not been effective. The preferred route of administration is transdermal — creams or patches — because oral testosterone has a less favorable effect on liver metabolism and lipid profiles. The goal is to restore testosterone to premenopausal physiologic levels, not to push it higher.
The guidelines are equally clear about what they do not recommend. They advise against using testosterone for general well-being, anti-aging, musculoskeletal health, or cognitive enhancement, because the evidence does not support these uses. They recommend against pellet implants. They recommend against prescribing testosterone to premenopausal women outside of clinical trials. And they emphasize that testosterone therapy should not be initiated without first optimizing estrogen-based HRT, because many symptoms attributed to low testosterone — fatigue, mood changes, low energy — may resolve with adequate estrogen replacement alone. The NICE guidelines in the United Kingdom echo this framework, stating that testosterone can be considered for menopausal women with low sexual desire if HRT alone has not been effective.
A New Drug That Could Change the Landscape
One reason the testosterone-for-women conversation may shift in coming years is AVA-291, a next-generation testosterone therapy being developed by Aviva Bio specifically for women. What makes AVA-291 different from standard testosterone is that it is engineered to resist aromatization — the enzymatic process by which testosterone converts into estrogen in the body. This matters because one of the longstanding safety concerns about testosterone therapy in women is whether that estrogen conversion could stimulate breast tissue and potentially increase breast cancer risk.
New data from Aviva Bio shows that AVA-291 has approximately 1,000-fold lower potential to stimulate breast cancer cell proliferation compared to ordinary testosterone. The FDA has provided guidance on a development pathway for AVA-291 following a Type B meeting, and the company plans to initiate a Phase 1 clinical trial in early 2026. If the drug proves safe and effective in trials, it would be the first testosterone therapy designed and approved for women — a development that could fundamentally change prescribing patterns by removing the off-label barrier that keeps most doctors from offering it.
What This Means for Brain Health and the Road Ahead
For readers following this topic through the lens of dementia prevention and cognitive health, the honest assessment is that testosterone therapy is not currently a brain health intervention for women. The hypothesis that androgens may play a protective role in female cognitive aging is scientifically interesting but clinically unproven. No guideline recommends testosterone for this purpose, and pursuing it based on preliminary or speculative data would mean accepting known risks — acne, hair growth, and the unknowns of long-term cardiovascular and breast cancer effects — for an undemonstrated benefit.
What is worth watching is the broader research trajectory. If AVA-291 or a similar product reaches FDA approval, it will generate the kind of large-scale, long-term clinical data that has been missing for decades. That data may eventually clarify whether testosterone has cognitive effects in women, for better or worse. In the meantime, the most defensible approach for women concerned about both sexual health and brain health after menopause is to work with a knowledgeable physician, optimize established therapies first, and treat testosterone as what the evidence currently supports it to be — a targeted treatment for one specific condition, not a broad anti-aging solution.
Conclusion
Testosterone therapy for postmenopausal women with low sexual desire is a legitimate, guideline-supported treatment that most doctors nonetheless avoid offering. The reason is structural rather than scientific: no FDA-approved product exists for women, which means no standardized dosing, no commercial formulation designed for female physiology, and significant liability exposure for prescribing physicians. Women who do seek it out navigate a fragmented landscape of off-label prescriptions, compounding pharmacies, and wellness clinics of varying quality. The path forward likely depends on whether the regulatory gap closes.
AVA-291 represents the most promising attempt to do exactly that, with a novel approach to the breast cancer safety concern that has stalled previous efforts. For women dealing with HSDD now, the best course is to find a menopause-informed physician willing to prescribe transdermal testosterone at physiologic doses with appropriate monitoring — and to be wary of clinics offering testosterone as a cure-all for aging. The evidence supports a specific, limited use. Respecting those boundaries is how women get the benefit without the unnecessary risk.
Frequently Asked Questions
Is testosterone therapy FDA-approved for women?
No. There are zero FDA-approved testosterone therapies formulated for women in the United States, despite more than 30 approved products for men. Doctors who prescribe it for women do so off-label, using male formulations at reduced doses.
What is the only proven benefit of testosterone therapy for women?
The only evidence-backed indication is hypoactive sexual desire disorder (HSDD) — a persistent loss of sexual desire after menopause. Claims about improved mood, cognition, energy, or muscle tone are not supported by rigorous clinical evidence.
How long does testosterone therapy take to work for low libido?
Women typically notice improvement in sexual function six to eight weeks after starting treatment, with maximal effects at approximately 12 weeks.
Are testosterone pellets safe for women?
Guidelines endorsed by 12 major medical societies recommend against hormone pellets for women. Pellets are unregulated, deliver doses that cannot be adjusted once implanted, and carry a higher risk of pushing testosterone to supraphysiologic levels, which can cause irreversible side effects like voice deepening.
What monitoring is needed during testosterone therapy?
Expert recommendations call for measuring testosterone levels at baseline, again at three to six weeks after starting therapy, and every six months thereafter. This ongoing monitoring screens for overuse and side effects including acne and unwanted hair growth.
Could testosterone therapy help prevent dementia or cognitive decline in women?
There is currently no clinical evidence supporting testosterone therapy for cognitive decline or dementia prevention in women. While some preliminary research has explored the hypothesis, no guidelines recommend it for this purpose. This remains an open research question.
